European drug regulators said on Friday that a batch of Johnson & Johnson COVID-19 vaccine manufactured for the region at a time when pollution problems were revealed at a U.S. manufacturing site would not be used as a precautionary measure. Stated.
The European Medicines Agency (EMA) did not disclose how many times it was affected, but Reuters required millions of doses and J & J achieved its goal of delivering 55 million doses to Europe by the end of June. It reports that it is getting harder to do.
J & J did not immediately respond to Reuters’ question.
The EMA is aware that a batch of active ingredients in J & J’s COVID-19 vaccine was contaminated with another vaccine material manufactured at Emergent Biosolutions’ site in Maryland in April. Said.
On-site production of J & J’s vaccine was stopped by US authorities and J & J was responsible for factory production.
The US Food and Drug Administration (FDA) is about to approve about 10 million factory-produced vaccines, CNN reported Friday.
The April error contained a source for AstraZeneca’s COVID-19 vaccine, which was also factory-produced and contaminated a batch of J & J vaccines developed by Janssen Unit.
The EMA said the batch was not intended for the European Union and that the vaccine batch released in the region was not affected by cross-contamination, based on the information it has.